TMCnet News

Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates
[July 30, 2020]

Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates


-- Company to host Conference Call and Webcast on August 13, 2020 at 8:00 a.m. ET --

SHANGHAI and SAN FRANCISCO, July 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced it will report financial results for the six months ended June 30, 2020 and corporate updates before the market opens on Thursday, August 13, 2020.

Conference Call and Webcast Information

Zai Lab will host a live conference call and webcast on August 13, 2020 at 8:00 a.m. ET. Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows:

Registration Link:http://apac.directeventreg.com/registration/event/7077004
  
Conference ID:7077004

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a uniqueaccess PIN, which can be used to join the conference call.



A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://ir.zailaboratory.com.


About Zai Lab

Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab
Billy Cho, CFO
+86 137 6151 2501
[email protected]

Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315/364
[email protected] / [email protected]

Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
[email protected] / [email protected]

Zai Lab Limited 

Primary Logo


[ Back To TMCnet.com's Homepage ]